Maxhimer Justin B, Reddy Rishindra M, Zuo Jingtong, Cole George W, Schrump David S, Nguyen Dao M
Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1502, USA.
J Thorac Cardiovasc Surg. 2005 Jan;129(1):53-63. doi: 10.1016/j.jtcvs.2004.07.051.
Histone deacetylase inhibitors mediate a potent growth-inhibitory effect in cancer cells through induction of cell-cycle arrest and apoptosis. Moreover, these agents significantly induce transcriptional activation of nuclear factor kappaB, as well as p21 regulated by protein kinase C, and are thought to negatively influence the ability of histone deacetylase inhibitor to effectively mediate apoptosis. This study aimed to evaluate the effect of calphostin C (a protein kinase C inhibitor) on trichostatin A (a histone deacetylase inhibitor)-mediated upregulation of nuclear factor kappaB and p21 promotor transcriptional activity, as well as induction of apoptosis in lung and esophageal cancer cells.
Cultured lung and esophageal cancer cells were treated with calphostin C and trichostatin A. Nuclear factor kappaB transcriptional activity was quantitated by using the nuclear factor kappaB-luciferase assay. Transcription of p21 gene and p21 protein levels was evaluated by using the p21 promoter-luciferase assay and the p21 enzyme-linked immunoassay, respectively. Apoptosis was evaluated by using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-based ApoBrdU assay. Levels of expression of nuclear factor kappaB-dependent antiapoptotic and proapoptotic proteins were evaluated by means of Western blotting.
Exposure of lung or esophageal cancer cells to trichostatin A resulted in a dose- and cell-dependent 2-fold to greater than 20-fold increase of nuclear factor kappaB and p21 transcriptional activity. Treatment with trichostatin A and calphostin C led to a 50% to 90% decrease of trichostatin A- mediated upregulation of nuclear factor kappaB and p21 activation. Inhibition of nuclear factor kappaB activity resulted in significant reduction (30% to >99%) of trichostatin A- mediated activation of not only nuclear factor kappaB transcription but also p21 promotor activity. Importantly, 90% to 96% of thoracic cancer cells under-went apoptosis after exposure to the combination of trichostatin A plus calphostin C.
Inhibition of protein kinase C abrogates trichostatin A-mediated upregulation of nuclear factor kappaB transcriptional activity and p21 expression that is associated with profound induction of apoptosis in lung or esophageal cancer cells. Protein kinase C might be a novel target for enhancing the efficacy of histone deacetylase inhibitor in cancer therapy.
组蛋白脱乙酰酶抑制剂通过诱导细胞周期停滞和凋亡,在癌细胞中发挥强大的生长抑制作用。此外,这些药物可显著诱导核因子κB的转录激活以及蛋白激酶C调节的p21,并且被认为会对组蛋白脱乙酰酶抑制剂有效介导凋亡的能力产生负面影响。本研究旨在评估钙泊三醇C(一种蛋白激酶C抑制剂)对曲古抑菌素A(一种组蛋白脱乙酰酶抑制剂)介导的核因子κB上调和p21启动子转录活性的影响,以及对肺癌和食管癌细胞凋亡的诱导作用。
用钙泊三醇C和曲古抑菌素A处理培养的肺癌和食管癌细胞。使用核因子κB-荧光素酶测定法定量核因子κB转录活性。分别使用p21启动子-荧光素酶测定法和p21酶联免疫测定法评估p21基因的转录和p21蛋白水平。使用基于末端脱氧核苷酸转移酶介导的dUTP缺口末端标记的ApoBrdU测定法评估凋亡。通过蛋白质印迹法评估核因子κB依赖性抗凋亡和促凋亡蛋白的表达水平。
肺癌或食管癌细胞暴露于曲古抑菌素A导致核因子κB和p21转录活性呈剂量和细胞依赖性增加2倍至超过20倍。用曲古抑菌素A和钙泊三醇C处理导致曲古抑菌素A介导的核因子κB上调和p21激活降低50%至90%。核因子κB活性的抑制导致曲古抑菌素A介导的不仅核因子κB转录激活而且p21启动子活性的显著降低(30%至>99%)。重要的是,90%至96%的胸癌细胞在暴露于曲古抑菌素A加钙泊三醇C的组合后发生凋亡。
蛋白激酶C的抑制消除了曲古抑菌素A介导的核因子κB转录活性上调和p21表达,这与肺癌或食管癌细胞中深刻的凋亡诱导相关。蛋白激酶C可能是提高组蛋白脱乙酰酶抑制剂在癌症治疗中疗效的新靶点。